JP2017510559A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017510559A5 JP2017510559A5 JP2016553491A JP2016553491A JP2017510559A5 JP 2017510559 A5 JP2017510559 A5 JP 2017510559A5 JP 2016553491 A JP2016553491 A JP 2016553491A JP 2016553491 A JP2016553491 A JP 2016553491A JP 2017510559 A5 JP2017510559 A5 JP 2017510559A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- binding fragment
- seq
- egfrviii
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims description 60
- 239000000427 antigen Substances 0.000 claims description 58
- 102000036639 antigens Human genes 0.000 claims description 58
- 108091007433 antigens Proteins 0.000 claims description 58
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 claims description 19
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 14
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 12
- 101710112752 Cytotoxin Proteins 0.000 claims description 8
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 8
- 239000002619 cytotoxin Substances 0.000 claims description 8
- 238000003556 assay Methods 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims description 6
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 229940127089 cytotoxic agent Drugs 0.000 claims description 4
- 239000000539 dimer Substances 0.000 claims description 4
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical class FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 2
- 229940035676 analgesics Drugs 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 108010044540 auristatin Proteins 0.000 claims description 2
- 238000010494 dissociation reaction Methods 0.000 claims description 2
- 230000005593 dissociations Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- VQNATVDKACXKTF-XELLLNAOSA-N duocarmycin Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 claims description 2
- 229960005501 duocarmycin Drugs 0.000 claims description 2
- 229930184221 duocarmycin Natural products 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims description 2
- 102000045108 human EGFR Human genes 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 231100000765 toxin Toxicity 0.000 claims description 2
- 230000004614 tumor growth Effects 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 231100000433 cytotoxic Toxicity 0.000 claims 2
- 230000001472 cytotoxic effect Effects 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 239000000611 antibody drug conjugate Substances 0.000 description 7
- 229940049595 antibody-drug conjugate Drugs 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 210000000481 breast Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461950963P | 2014-03-11 | 2014-03-11 | |
| US61/950,963 | 2014-03-11 | ||
| PCT/US2015/019722 WO2015138460A1 (en) | 2014-03-11 | 2015-03-10 | Anti-egfrviii antibodies and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017510559A JP2017510559A (ja) | 2017-04-13 |
| JP2017510559A5 true JP2017510559A5 (esLanguage) | 2018-04-19 |
| JP6632984B2 JP6632984B2 (ja) | 2020-01-22 |
Family
ID=52875228
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016553491A Active JP6632984B2 (ja) | 2014-03-11 | 2015-03-10 | 抗ＥＧＦＲｖＩＩＩ抗体およびその使用 |
Country Status (31)
Families Citing this family (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR095196A1 (es) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
| MY178160A (en) | 2014-03-11 | 2020-10-06 | Regeneron Pharma | Anti-egfrviii antibodies and uses thereof |
| MX382902B (es) * | 2014-10-31 | 2025-03-13 | Oncomed Pharm Inc | Inhibidor de la vía noth en combinación con un agente inmunoterapéutico para usarse en el tratamiento de cáncer. |
| TWI899515B (zh) | 2015-08-04 | 2025-10-01 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法 |
| MA45517B1 (fr) * | 2015-10-23 | 2021-04-30 | Merus Nv | Molécules de liaison inhibant la croissance de cancer |
| EP3504328A1 (en) | 2016-08-24 | 2019-07-03 | Regeneron Pharmaceuticals, Inc. | Host cell protein modification |
| JP7313684B2 (ja) * | 2016-11-21 | 2023-07-25 | キュレアブ ゲーエムベーハー | 抗ｇｐ７３抗体及びイムノコンジュゲート |
| IL313695A (en) * | 2017-02-10 | 2024-08-01 | Regeneron Pharma | Radiolabeled anti-lag3 antibodies for immuno-pet imaging |
| CN110914293B (zh) | 2017-07-06 | 2024-08-13 | 里珍纳龙药品有限公司 | 用于制备糖蛋白的细胞培养工艺 |
| TWI799432B (zh) * | 2017-07-27 | 2023-04-21 | 美商再生元醫藥公司 | 抗ctla-4抗體及其用途 |
| AU2018312816B2 (en) | 2017-08-09 | 2021-05-27 | Merus N.V. | Antibodies that bind EGFR and cMET |
| WO2019035630A2 (ko) * | 2017-08-14 | 2019-02-21 | 사회복지법인 삼성생명공익재단 | 인간 상피 성장 인자 수용체 변이체 ⅲ에 결합하는 항체 및 그의 항체 단편 |
| US20210032351A1 (en) * | 2017-12-13 | 2021-02-04 | Xdcexplorer (Shanghai) Co., Ltd. | Egfrviii antibody and conjugate, and preparation method and use thereof |
| CA3084059A1 (en) | 2017-12-22 | 2019-06-27 | Regeneron Pharmaceuticals, Inc. | System and method for characterizing drug product impurities |
| BR112020013336A2 (pt) | 2018-01-31 | 2020-12-01 | Regeneron Pharmaceuticals, Inc. | produto farmacêutico proteico, métodos para caracterizar as impurezas do produto farmacêutico proteico de alto peso molecular intermediário, para produção de um anticorpo, e para caracterizar as impurezas de fármaco com variação de carga, anticorpo, e, sistema para caracterizar impurezas de fármaco de alto peso molecular intermediário. |
| TWI786265B (zh) | 2018-02-02 | 2022-12-11 | 美商再生元醫藥公司 | 用於表徵蛋白質二聚合之系統及方法 |
| KR20260004591A (ko) | 2018-02-28 | 2026-01-08 | 리제너론 파마슈티칼스 인코포레이티드 | 바이러스 오염물질을 확인하기 위한 시스템 및 방법 |
| IL277264B2 (en) | 2018-03-19 | 2024-03-01 | Regeneron Pharma | Microchip capillary electrophoresis assays and reagents |
| US12253490B2 (en) | 2018-03-19 | 2025-03-18 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| US12259355B2 (en) | 2018-03-19 | 2025-03-25 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| TW202016125A (zh) | 2018-05-10 | 2020-05-01 | 美商再生元醫藥公司 | 用於定量及調節蛋白質黏度之系統與方法 |
| AU2019329686A1 (en) | 2018-08-27 | 2020-12-03 | Regeneron Pharmaceuticals, Inc. | Use of raman spectroscopy in downstream purification |
| AU2019333047A1 (en) | 2018-08-30 | 2020-12-03 | Regeneron Pharmaceuticals, Inc. | Methods for characterizing protein complexes |
| US11579150B2 (en) | 2019-01-16 | 2023-02-14 | Regeneron Pharmaceuticals, Inc. | Methods for characterizing disulfide bonds |
| EA202192413A1 (ru) | 2019-03-27 | 2021-12-30 | Нэшнл Рисеч Каунсил Оф Канада | АНТИТЕЛА ПРОТИВ EGFRvIII И ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ФРАГМЕНТЫ |
| KR20220007586A (ko) | 2019-05-13 | 2022-01-18 | 리제너론 파마슈티칼스 인코포레이티드 | 개선된 경쟁적 리간드 결합 검정 |
| EP3994173A1 (en) * | 2019-07-02 | 2022-05-11 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Monoclonal antibodies that bind egfrviii and their use |
| CN114667450B (zh) | 2019-09-24 | 2025-05-02 | 里珍纳龙药品有限公司 | 用于色谱介质的使用和再生的系统及方法 |
| US12297451B1 (en) | 2019-10-25 | 2025-05-13 | Regeneron Pharmaceuticals, Inc. | Cell culture medium |
| BR112022009974A2 (pt) | 2019-11-25 | 2022-08-16 | Regeneron Pharma | Métodos de produção de um polímero ou micropartículas revestidas com polímero, para produzir microesferas poliméricas ou revestidas com polímero e para produzir micropartículas, composição de liberação sustentada, micropartículas, e, composição farmacêutica |
| CA3165060C (en) | 2020-01-21 | 2023-06-20 | Yiming Zhao | Deglycosylation methods for electrophoresis of glycosylated proteins |
| US20230192866A1 (en) * | 2020-04-24 | 2023-06-22 | Merus N.V. | Treatment of cancers with an antibody that binds lgr5 and egfr |
| TW202432837A (zh) | 2020-08-31 | 2024-08-16 | 美商再生元醫藥公司 | 用以改良細胞培養效能及減少天冬醯胺序列變異之天冬醯胺饋料策略 |
| WO2022115588A1 (en) | 2020-11-25 | 2022-06-02 | Regeneron Pharmaceuticals, Inc. | Sustained release formulations using non-aqueous membrane emulsification |
| CN116710124A (zh) | 2020-12-17 | 2023-09-05 | 瑞泽恩制药公司 | 包封蛋白质的微凝胶的制造 |
| WO2022133169A1 (en) | 2020-12-18 | 2022-06-23 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
| AU2022209730A1 (en) | 2021-01-20 | 2023-07-13 | Regeneron Pharmaceuticals, Inc. | Methods of improving protein titer in cell culture |
| US20240228629A1 (en) * | 2021-02-16 | 2024-07-11 | City Of Hope | Anti-domain iv egfr antibodies and uses thereof |
| BR112023017442A2 (pt) | 2021-03-03 | 2023-09-26 | Regeneron Pharma | Métodos para identificar regiões em uma proteína e para modificar a viscosidade de uma droga proteica, e, droga proteica |
| BR112023018665A2 (pt) | 2021-03-26 | 2023-10-03 | Regeneron Pharma | Métodos e sistemas para desenvolvimento de protocolos de mistura |
| KR20240015646A (ko) | 2021-06-01 | 2024-02-05 | 리제너론 파마슈티칼스 인코포레이티드 | 마이크로칩 모세관 전기영동 분석 및 시약 |
| CA3212850A1 (en) | 2021-06-22 | 2022-12-29 | Frank DELFINO | Anti-egfrviii antibody drug conjugates and uses thereof |
| US20230077710A1 (en) | 2021-09-08 | 2023-03-16 | Regeneron Pharmaceuticals, Inc. | HIGH-THROUGHPUT AND MASS-SPECTROMETRY-BASED METHOD FOR QUANTITATING ANTIBODIES AND OTHER Fc-CONTAINING PROTEINS |
| CA3232463A1 (en) | 2021-09-20 | 2023-03-23 | Philip Mellors | Methods of controlling antibody heterogeneity |
| JP2024539550A (ja) * | 2021-09-29 | 2024-10-29 | ナショナル リサーチ カウンシル オブ カナダ | ヒト化抗ｅｇｆｒｖｉｉｉ抗体及びその抗原結合断片 |
| US20230110811A1 (en) | 2021-10-07 | 2023-04-13 | Regeneron Pharmaceuticals, Inc. | pH METER CALIBRATION AND CORRECTION |
| IL311245A (en) | 2021-10-07 | 2024-05-01 | Regeneron Pharma | Systems and methods for pH modeling and control |
| EP4423018A1 (en) | 2021-10-26 | 2024-09-04 | Regeneron Pharmaceuticals, Inc. | Systems and methods for generating laboratory water and distributing laboratory water at different temperatures |
| AU2023233590A1 (en) | 2022-03-18 | 2024-10-17 | Regeneron Pharmaceuticals, Inc. | Methods and systems for analyzing polypeptide variants |
| US20230416396A1 (en) * | 2022-05-18 | 2023-12-28 | Regeneron Pharmaceuticals, Inc. | Multispecific antigen binding molecules that bind cd38 and 4-1bb, and uses thereof |
| WO2024130048A1 (en) | 2022-12-16 | 2024-06-20 | Regeneron Pharmaceuticals, Inc. | Methods and systems for assessing chromatographic column integrity |
| US20240245779A1 (en) | 2023-01-25 | 2024-07-25 | Regeneron Pharmaceuticals, Inc. | Methods of modeling liquid protein composition stability |
| EP4655595A1 (en) | 2023-01-25 | 2025-12-03 | Regeneron Pharmaceuticals, Inc. | Mass spectrometry-based characterization of antibodies co-expressed in vivo |
| US20240255519A1 (en) | 2023-02-01 | 2024-08-01 | Regeneron Pharmaceuticals, Inc. | Asymmetrical flow field-flow fractionation with mass spectrometry for biomacromolecule analysis |
| WO2024178213A2 (en) | 2023-02-22 | 2024-08-29 | Regeneron Pharmaceuticals, Inc. | System suitability parameters and column aging |
| US20240366471A1 (en) | 2023-05-01 | 2024-11-07 | Regeneron Pharmaceuticals, Inc. | Multidose antibody drug products using phenol or benzyl alcohol |
| UY40783A (es) | 2023-06-12 | 2024-12-31 | Amgen Inc | Proteínas de unión a agonistas del receptor beta de linfotoxina |
| AU2024296940A1 (en) * | 2023-07-07 | 2026-01-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Humanized 40h3 antibody |
| WO2025054406A1 (en) | 2023-09-08 | 2025-03-13 | Regeneron Pharmaceuticals, Inc. | Methods and systems for assessing chromatographic column integrity |
| US20250095773A1 (en) | 2023-09-18 | 2025-03-20 | Regeneron Pharmaceuticals, Inc. | Methods and systems for developing chromatography protocols |
| WO2025072597A2 (en) | 2023-09-29 | 2025-04-03 | Regeneron Pharmaceuticals, Inc. | Lyophilization using controlled nucleation |
| US20250129117A1 (en) | 2023-10-18 | 2025-04-24 | Regeneron Pharmaceuticals, Inc. | Rapid purification of monoclonal antibody from in-process upstream cell culture material |
| TW202535934A (zh) | 2023-11-02 | 2025-09-16 | 美商再生元醫藥公司 | 利用應力來降低脂酶活性的方法 |
| WO2025166281A1 (en) | 2024-02-01 | 2025-08-07 | Regeneron Pharmaceuticals, Inc. | Platform for charge-detection mass spectrometry analysis of aavs |
| WO2025175164A1 (en) | 2024-02-16 | 2025-08-21 | Regeneron Pharmaceuticals, Inc. | Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods |
| WO2025194043A1 (en) | 2024-03-15 | 2025-09-18 | Regeneron Pharmaceuticals, Inc. | Polysorbate and polyoxyethylene sorbitan as excipients for stable protein formulations |
| WO2025259840A1 (en) | 2024-06-13 | 2025-12-18 | Regeneron Pharmaceuticals, Inc. | Methods and systems for scaled chromatography |
| WO2026025058A1 (en) | 2024-07-25 | 2026-01-29 | Regeneron Pharmaceuticals, Inc. | Aav viral particles retargeted to egfr-expressing cancer cells |
| WO2026025028A1 (en) | 2024-07-26 | 2026-01-29 | Regeneron Pharmaceuticals, Inc. | Methods of making ultra-high concentrated protein formulations using lyophilization |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP0491007B1 (en) | 1989-09-08 | 1996-03-13 | The Johns Hopkins University | Structural alterations of the egf receptor gene in human gliomas |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| DE69233254T2 (de) | 1991-06-14 | 2004-09-16 | Genentech, Inc., South San Francisco | Humanisierter Heregulin Antikörper |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| US7060808B1 (en) | 1995-06-07 | 2006-06-13 | Imclone Systems Incorporated | Humanized anti-EGF receptor monoclonal antibody |
| AUPP380498A0 (en) | 1998-05-29 | 1998-06-25 | Biomolecular Research Institute Limited | Egf receptor agonists and antagonists |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| US20070258987A1 (en) | 2000-11-28 | 2007-11-08 | Seattle Genetics, Inc. | Recombinant Anti-Cd30 Antibodies and Uses Thereof |
| US20100056762A1 (en) * | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
| ATE446317T1 (de) | 2001-05-11 | 2009-11-15 | Ludwig Inst For Cancer Res Ltd | Spezifische bindungsproteine und ihre verwendung |
| US7744882B2 (en) | 2001-05-31 | 2010-06-29 | Tumor Biology Investment Group, Inc. | Soluble ErbB3 methods of detection and antibodies |
| US20040248196A1 (en) | 2001-08-03 | 2004-12-09 | Adams Timothy Edward | Methods of screening based on the egf receptor crystal structure |
| KR101435167B1 (ko) | 2003-06-27 | 2014-11-04 | 암젠 프레몬트 인코포레이티드 | 상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그용도 |
| US7767792B2 (en) | 2004-02-20 | 2010-08-03 | Ludwig Institute For Cancer Research Ltd. | Antibodies to EGF receptor epitope peptides |
| WO2005082023A2 (en) | 2004-02-23 | 2005-09-09 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| TW200539855A (en) | 2004-03-15 | 2005-12-16 | Wyeth Corp | Calicheamicin conjugates |
| US20110142822A1 (en) * | 2004-06-14 | 2011-06-16 | Kussie Paul H | Crystal of egfr extracellular domain and cetuximab fab fragment, and uses thereof |
| AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
| US7750116B1 (en) | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
| SI2041177T1 (sl) | 2006-06-02 | 2012-03-30 | Regeneron Pharma | Visoko afinitetna protitelesa za humani IL receptor |
| RU2448979C2 (ru) | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Антитела человека к дельта-подобному лиганду-4 человека |
| WO2008122039A2 (en) | 2007-04-02 | 2008-10-09 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Selenocysteine mediated hybrid antibody molecules |
| CA2687178C (en) | 2007-05-23 | 2014-02-04 | Ventana Medical Systems, Inc. | Polymeric carriers for immunohistochemistry and in situ hybridization |
| WO2009067242A2 (en) | 2007-11-20 | 2009-05-28 | Imclone Llc | Co-crystal of antibody 11f8 fab fragment and egfr extracellular domain and uses thereof |
| US20090269343A1 (en) * | 2008-04-11 | 2009-10-29 | Duke University | Dual Specific Immunotoxin for Brain Tumor Therapy |
| AU2009243009B2 (en) | 2008-04-30 | 2014-09-11 | Immunogen, Inc | Potent conjugates and hydrophilic linkers |
| EP2326349B1 (en) | 2008-07-21 | 2015-02-25 | Polytherics Limited | Novel reagents and method for conjugating biological molecules |
| AR075896A1 (es) | 2009-03-20 | 2011-05-04 | Genentech Inc | Anticuerpos anti-her (factor de crecimiento epidermico) |
| CA2764370C (en) | 2009-06-02 | 2018-08-21 | Regeneron Pharmaceuticals, Inc. | Fucosylation-deficient cells |
| JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| DK2889624T3 (en) | 2009-08-10 | 2018-12-10 | Ucl Business Plc | Reversible covalent bonding of functional molecules |
| TWI540136B (zh) | 2010-04-15 | 2016-07-01 | 梅迪繆思有限公司 | 吡咯并苯并二氮呯及其共軛物 |
| US20130244905A1 (en) | 2010-07-06 | 2013-09-19 | Ed Grabczyk | Reporter for RNA Polymerase II Termination |
| CN103717262B (zh) * | 2011-03-29 | 2017-09-15 | 伊缪诺金公司 | 通过一步法制备类美登素抗体缀合物 |
| MX371526B (es) | 2011-05-27 | 2020-01-31 | Ambrx Inc | Composiciones que contienen, metodos que incluyen, y usos de derivados de dolastatina enlazados a aminoacidos no naturales. |
| US8815226B2 (en) | 2011-06-10 | 2014-08-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| KR101961976B1 (ko) | 2011-10-14 | 2019-03-25 | 시애틀 지네틱스, 인크. | 피롤로벤조디아제핀 및 표적 접합체 |
| CN103987384A (zh) | 2011-10-14 | 2014-08-13 | 西雅图基因公司 | 吡咯并苯并二氮杂卓和靶向结合物 |
| WO2013053872A1 (en) | 2011-10-14 | 2013-04-18 | Spirogen Sàrl | Synthesis method and intermediates useful in the preparation of pyrrolobenzodiazepines |
| CA2850103C (en) | 2011-10-14 | 2019-09-10 | Spirogen Sarl | Pyrrolobenzodiazepines |
| WO2013068874A1 (en) | 2011-11-11 | 2013-05-16 | Pfizer Inc. | Antibody-drug conjugates |
| US20140314667A1 (en) * | 2011-11-16 | 2014-10-23 | Amgen Inc. | Methods of treating epidermal growth factor deletion mutant viii related disorders |
| CA2857398A1 (en) | 2011-12-05 | 2013-06-13 | Igenica Biotherapeutics, Inc. | Antibody-drug conjugates and related compounds, compositions, and methods |
| EP2968593B1 (en) * | 2013-03-15 | 2024-11-20 | Regeneron Pharmaceuticals, Inc. | Biologically active molecules, conjugates thereof, and therapeutic uses |
| HUE054057T2 (hu) | 2013-08-07 | 2021-08-30 | Affimed Gmbh | EGFRvIII specifikus antitest-kötõhelyek |
| MY178160A (en) | 2014-03-11 | 2020-10-06 | Regeneron Pharma | Anti-egfrviii antibodies and uses thereof |
-
2015
- 2015-03-10 MY MYPI2016703057A patent/MY178160A/en unknown
- 2015-03-10 US US14/643,886 patent/US9475875B2/en active Active
- 2015-03-10 EP EP15712472.8A patent/EP3126388B1/en active Active
- 2015-03-10 JP JP2016553491A patent/JP6632984B2/ja active Active
- 2015-03-10 AU AU2015229591A patent/AU2015229591B2/en active Active
- 2015-03-10 PL PL15712472T patent/PL3126388T3/pl unknown
- 2015-03-10 DK DK15712472.8T patent/DK3126388T3/da active
- 2015-03-10 EA EA201691824A patent/EA035809B1/ru unknown
- 2015-03-10 MA MA39313A patent/MA39313B1/fr unknown
- 2015-03-10 CA CA2940685A patent/CA2940685C/en active Active
- 2015-03-10 SM SM20190439T patent/SMT201900439T1/it unknown
- 2015-03-10 RS RS20191002A patent/RS59077B1/sr unknown
- 2015-03-10 WO PCT/US2015/019722 patent/WO2015138460A1/en not_active Ceased
- 2015-03-10 ES ES15712472T patent/ES2736126T3/es active Active
- 2015-03-10 SI SI201530830T patent/SI3126388T1/sl unknown
- 2015-03-10 MX MX2016011619A patent/MX373280B/es active IP Right Grant
- 2015-03-10 HR HRP20191335TT patent/HRP20191335T1/hr unknown
- 2015-03-10 KR KR1020167025833A patent/KR102399005B1/ko active Active
- 2015-03-10 CN CN201580024031.3A patent/CN106459199B/zh active Active
- 2015-03-10 HU HUE15712472A patent/HUE045307T2/hu unknown
- 2015-03-10 PT PT15712472T patent/PT3126388T/pt unknown
- 2015-03-10 NZ NZ724229A patent/NZ724229A/en unknown
- 2015-03-10 BR BR112016020752-1A patent/BR112016020752B1/pt active IP Right Grant
- 2015-03-10 SG SG11201606979TA patent/SG11201606979TA/en unknown
- 2015-03-10 LT LTEP15712472.8T patent/LT3126388T/lt unknown
- 2015-03-10 ME MEP-2019-202A patent/ME03525B/me unknown
-
2016
- 2016-06-01 US US15/170,628 patent/US10047160B2/en active Active
- 2016-08-21 IL IL247407A patent/IL247407B/en active IP Right Grant
- 2016-08-23 PH PH12016501680A patent/PH12016501680B1/en unknown
- 2016-08-24 ZA ZA2016/05894A patent/ZA201605894B/en unknown
- 2016-09-06 CL CL2016002252A patent/CL2016002252A1/es unknown
-
2018
- 2018-07-12 US US16/033,477 patent/US10738124B2/en active Active
-
2019
- 2019-08-08 CY CY20191100847T patent/CY1121870T1/el unknown
-
2020
- 2020-07-01 US US16/918,656 patent/US11608380B2/en active Active